Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07102589 | SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection(SWEEP) | recruiting | — | 100 | Seoul National University Bundang HospitalOTHER | 1 | Aug 4, 2025 | clinicaltrials |
| NCT05442060 | To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer(EGFR) | recruiting | Phase 2 | 60 | OBI Pharma, IncINDUSTRY |
| 1 |
| Aug 3, 2025 |
| clinicaltrials |
| NCT04706754 | Pan-Canadian Lung Cancer Observational Study (PALEOS) | recruiting | — | 25,000 | William Osler Health SystemOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06417008 | A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,080 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06462963 | OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)(SPRINT) | recruiting | N/A | 302 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Aug 1, 2025 | clinicaltrials |
| NCT06691776 | Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)(FASCINATE) | recruiting | N/A | 100 | The Netherlands Cancer InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06897046 | Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC | recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07099027 | The Lung Health Check Pilot | recruiting | N/A | 2,183 | Royal College of Surgeons, IrelandOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04209218 | Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery | recruiting | N/A | 1,988 | Peking University First HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07087080 | Plasma Metabolomics as a Tool to Distinguish PET-positive Malignant From PET-positive Benign Nodules | recruiting | N/A | 350 | Hasselt UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07096258 | EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients(EMPATHY NSCLC) | recruiting | — | 1,000 | Hedera Dx SAINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT07096882 | SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection | recruiting | Phase 1 | 22 | Cytocraft Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07014202 | Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy | recruiting | Phase 2 | 224 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | recruiting | Phase 4 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06864624 | Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC(WU-KONG20) | recruiting | Phase 2 | 27 | Tang-Du HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085182 | Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study | recruiting | Phase 2 | 20 | Zibo Municipal HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07086300 | Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC | recruiting | N/A | 120 | Kong FanmingOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07086456 | Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06734702 | Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | recruiting | Phase 3 | 497 | Sun Yat-sen UniversityOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06926140 | Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer | recruiting | N/A | 240 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06951464 | A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC | recruiting | Phase 2 | 40 | Sichuan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07052669 | Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC | recruiting | Phase 3 | 311 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04136535 | Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC(PCA) | recruiting | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07008287 | Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases | recruiting | — | 100 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06572540 | Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer | recruiting | N/A | 110 | Jiayuan SunOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06969014 | Transbronchial MWA for Pulmonary Tumors | recruiting | N/A | 15 | Shanghai Chest HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07048236 | Specimen and Clinical Data Collection Plan for LDCT Screening Participants | recruiting | — | 12,000 | Chung Shan Medical UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06347939 | Mediastinal EBUS Cryobiopsy Study In Sweden(MECRIS) | recruiting | — | 200 | Region SkaneOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06709859 | Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC | recruiting | Phase 2 | 30 | Shandong Public Health Clinical CenterOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07070011 | Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer | recruiting | — | 38 | Shanghai Chest Hospital of Shanghai Jiao Tong UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06167460 | Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. | recruiting | — | 50 | Gene SolutionsINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | recruiting | Phase 2 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06617936 | Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. | recruiting | Phase 2 | 36 | Hua ZhangOTHER_GOV | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05486650 | An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment | recruiting | — | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05754203 | Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC | recruiting | N/A | 40 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07062172 | Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer | recruiting | N/A | 1,753 | University of California, IrvineOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07059923 | Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung) | recruiting | — | 400 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06379087 | Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC | recruiting | Phase 2 | 20 | Ji YonglingOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06232083 | A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR) | recruiting | Phase 1 | 20 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06773507 | Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07037680 | Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT | recruiting | Phase 2 | 44 | JIANYANG WANGOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07057102 | Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer | recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07050043 | Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC(LEDANG) | recruiting | Phase 3 | 123 | Dr Arvindran A/L AlagaOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07051044 | Rapid Absorbance-based Detection of Inner Cheek Cell Abnormalities Using Light Spectroscopy for Risk Evaluation of Lung Cancer to Enable Critical Decision Support in Targeted Patient Populations(RADICAL-REACT) | recruiting | — | 450 | Sierra Medical Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047573 | Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules | recruiting | — | 150 | Zhao JunOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06946927 | A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation | recruiting | Phase 1 | 72 | JemincareINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2025source: clinicaltrials